Interestingly, BET inhibitors and DOT1L inhibitors are also effective in vitro in a variety of other leukemias [148] and hematologic malignancies such as multiple myeloma or Burkitt lymphoma [149,150], for which HOXA or c-myc activation are key drivers of the disease. The gene discussed is DNER; the disease is leukemia.